Quantum BioPharma (XCNQ:QNTM) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma 5-Year Dividend Growth Rate?

Quantum BioPharma's Dividends per Share for the three months ended in Dec. 2024 was C$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Quantum BioPharma's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Quantum BioPharma's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Quantum BioPharma's 5-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantum BioPharma's 5-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's 5-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

Quantum BioPharma 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Quantum BioPharma (XCNQ:QNTM) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Quantum BioPharma's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-3.638
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quantum BioPharma 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (XCNQ:QNTM) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

QNTM:USA 0K91:Germany

Address

55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7

Website

https://www.fsdpharma.com

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.